No increase in incidence or risk of recurrence of breast cancer in ospemifene-treated patients with vulvovaginal atrophy (VVA) was written by Cai, Bin;Simon, James;Villa, Paola;Biglia, Nicoletta;Panay, Nicholas;Djumaeva, Stora;Particco, Martire;Kanakamedala, Hemanth;Altomare, Corrado. And the article was included in Maturitas in 2020.Product Details of 128607-22-7 This article mentions the following:
To estimate the incidence and recurrence of breast cancer (BC) in patients with vulvovaginal atrophy (VVA) treated with ospemifene and matched untreated VVA patients using real-world data. Retrospective matched cohort study. Main Outcome Measures: VVA patients were identified from the 2011-2018 US MarketScan insurance claims database. For incidence, ospemifene-treated VVA patients without evidence of BC prior to index treatment were matched to two untreated VVA controls similarly without history of BC on age, index VVA year, geog. region, Charlson Comorbidity categories, and follow-up time. BC after the index treatment was identified by BC diagnosis codes, mastectomy, chemotherapy, or radiation procedure. Incidence rate, rate ratio (RR) and their 95% confidence intervals (CI) were calculated The process was repeated to estimate BC recurrence in patients with a history of BC in 1:1, 1:2 and 1:3 matches.1728 ospemifene users and 3456 untreated patients met the inclusion and matching criteria for assessing incidence. The average number of days for which ospemifene was supplied was 314 (standard deviation [SD] = 340). Average follow-up time from index treatment was 937 days (SD = 392) for treated patients and 915 days (SD = 396) for controls. BC incidence rates per 1000 person-years was 2.03 (95% CI: 1.06-3.91) for treated patients and 3.53 (95% CI: 2.49-4.99) for controls (RR = 0.58, 95% CI: 0.28-1.21). No difference in recurrence was observed between ospemifene-treated and matched untreated patients. Ten (32.3%) treated vs. 25 (40.3%) controls in the 1:2 matched anal. had a recurrence. No differences were observed in the BC incidence and recurrence rates in ospemifene users compared with matched controls. In the experiment, the researchers used many compounds, for example, (Z)-2-(4-(4-Chloro-1,2-diphenylbut-1-en-1-yl)phenoxy)ethan-1-ol (cas: 128607-22-7Product Details of 128607-22-7).
(Z)-2-(4-(4-Chloro-1,2-diphenylbut-1-en-1-yl)phenoxy)ethan-1-ol (cas: 128607-22-7) belongs to alcohols. The oxygen atom of the strongly polarized O―H bond of an alcohol pulls electron density away from the hydrogen atom. This polarized hydrogen, which bears a partial positive charge, can form a hydrogen bond with a pair of nonbonding electrons on another oxygen atom. Converting an alcohol to an alkene requires removal of the hydroxyl group and a hydrogen atom on the neighbouring carbon atom. Dehydrations are most commonly carried out by warming the alcohol in the presence of a strong dehydrating acid, such as concentrated sulfuric acid.Product Details of 128607-22-7
Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts